Excipient Nanoparticles Show Promise as Anti-Cancer Therapeutics

Researchers at University Teknologi MARA in Malaysia have made significant discoveries about the potential of excipients, typically considered inactive additives, to be used as anti-cancer therapeutics at the nanoscale. According to recent literature, excipient nanoparticles can stimulate reactive oxygen species production, trigger apoptosis, and regulate metastasis, making them a promising new approach to cancer treatment. This research has been peer-reviewed and published in the International Journal of Pharmaceutics.

Key Takeaways:

• Excipient nanoparticles can stimulate reactive oxygen species production, promoting oxidative damage to cancer cells.
• These nanoparticles can trigger apoptosis and regulate metastasis, making them a promising new approach to cancer treatment.
• The delivery specificity of excipient nanoparticles can be promoted using targeting ligands or by adapting cancer cell membranes.
• Excipient nanoparticles can be activated using light irradiation, ultrasound, or magnetic fields to initiate hyperthermia or localized electric fields.
• These nanoparticles are expected to have milder therapeutic effects and require prolonged treatment with higher dosages compared to drugs.
• Excipient nanoparticles are drug-free, which reduces manufacturing challenges such as premature drug leaching and systemic adverse effects.

Statistics:

• 2022-2025: Literature cited to support the potential of excipient nanoparticles as anti-cancer therapeutics.
• 125866: Article number for the research published in the International Journal of Pharmaceutics.
• 23: Excipients listed as having potential as anti-cancer therapeutics (chitosan, guar gum, arabic gum, pectin, kaolin, peptide, folic acid, and hyaluronic acid).

Sources:

• Excipient nanoparticles as cancer therapeutics: Mechanistic actions, delivery and manufacturing perspectives. International Journal of Pharmaceutics, 2025:125866.
• NewsRx. University Teknologi MARA Reports Findings in Cancer (Excipient nanoparticles as cancer therapeutics: Mechanistic actions, delivery and manufacturing perspectives). Nanotechnology Weekly. June 30, 2025; p 1568.